Login to Your Account

Amgen's Neupogen faces U.S. headwinds: Earnings

By Michael Fitzhugh
Staff Writer

Tuesday, January 27, 2015

Amgen Inc. reported after market close Tuesday that despite higher than expected fourth quarter profits, bolstered by strong sales of Enbrel (etanercept), sales of Neupogen (filgrastim) fell 11 percent year over year, driven by the impact of U.S. competition, inventory issues and foreign exchange rates.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription